more

Client Profile

Thermalin Diabetes, Inc.

Thermalin’s portfolio of next-generation insulin analogs fills multiple gaps in a rapidly growing $17B market. Thermalin’s world-class team is leveraging breakthroughs with significant IP built on 25 years of research on insulin by Dr. Michael Weiss, Chairman of Biochemistry at Case Western Reserve Medical School (CWRU). Our new molecules, novel formulations, and devices address unmet clinical needs, enable new delivery technologies and reach rapidly developing markets. For more information, please contact Richard Berenson (rick@thermalin.com).

CEO
Richard Berenson
Type of Business
Biotech
Number of Employees
7
Recent Successes
Closed a $2.85 million Series A investment round.